Thieme Hepatitis C: State of the Art at the Millennium: A Bound Compilation of Issues 1 and 2 of Seminars in Liver Disease (2000)

A timely collection of scientific & clinical information on Hepatitis C. A bound compilation of issues 1 and 2 of Seminars in Liver Disease, 2000. A hardbound compendium of Volume 20, Numbers 1 and 2 of the journal, Seminars in Liver Disease, this new volume brings together an international group of distinguished authors to present 16 current, incisive reviews and analyses of both the basic science and clinical aspects of HCV. The volume examines the broadest spectrum of HCV virology, pathology, and disease while focusing on the following key issues: HCV's impact on human populations The manifestations of the virus & its distribution throughout the body HCV molecular virology with an emphasis on its clinical implications Identification of pharmaceutical targets and vaccine components and an analysis of genotypes and interferon sensitivity In addition, the volume examines the clinical consequences of HCV infection, including immune response to HCV, B-cell abnormalities, diagnostic tests, kinetic studies, interferon-ribavirin combination therapy, liver transplantation, and vaccine development. From the Back Cover A hardbound compendium of Volume 20, Numbers 1 and 2 of the journal, Seminars in Liver Disease, this new volume brings together an international group of distinguished authors to present 16 current, incisive reviews and analyses of both the basic science and clinical aspects of HCV. The volume examines the broadest spectrum of HCV virology, pathology, and disease while focusing on the following key issues: HCV's impact on human populations The manifestations of the virus & its distribution throughout the body HCV molecular virology with an emphasis on its clinical implications Identification of pharmaceutical targets and vaccine components and an analysis of genotypes and interferon sensitivity In addition, the volume examines the clinical consequences of HCV infection, including immune response to HCV, B-cell abnormalities, diagnostic tests, kinetic studies, interferon-ribavirin combination therapy, liver transplantation, and vaccine development. About the Author National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland